Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000.
A total of 322 erythromycin-resistant pneumococci from TRUST 3 and TRUST 4 United States surveillance studies (1999-2000) were screened for 23S rRNA, L4, and L22 gene mutations. Nineteen isolates, two with mefA, had mutations at position 2058 or 2059 in 23S rRNA. Two had a 69GTG71-to-TPS substitution in L4; one of these also contained ermA.
Johnson & Johnson Pharmaceutical Research & Development, LLC, Room B225, 1000 Route 202, Raritan, New Jersey 08869. tdavies@prdus.jnj.com
Todd A
TA
Davies
Karen
K
Bush
Daniel
D
Sahm
Alan
A
Evangelista
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D004917:Erythromycin / Q000494:pharmacology; D006801:Humans; D007223:Infant; D018942:Macrolides / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009154:Mutation; D011159:Population Surveillance; D012338:RNA, Ribosomal, 23S / Q000235:genetics*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D014481:United States
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D018942:Macrolides; D012338:RNA, Ribosomal, 23S; D004917:Erythromycin